ArticleAdvanced biotechnology2026
A safety-aware intake modeling framework for translating edible algal biomass into nutritional bioproducts.
Article in Advanced biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Edible algal biomass has emerged as a promising platform for nutritional bioproduct development, but its practical translation depends on compositional variability, intake feasibility, and safety constraints. Here, we integrated biochemical profiling, trace element screening, age-specific intake modeling, and community consumption context to evaluate commercially available and supplier-provided microalgal and seaweed products within realistic application boundaries. Selected products differed substantially in macronutrient composition, fatty acid profiles, pigments, polyphenols, and mineral composition, indicating product- and species-specific roles as nutritional biomass rather than interchangeable ingredients. Across species and age groups, approximately 0.7 to 3.1 g dry biomass provided 20% of age-specific alpha-linolenic acid intake, with approximately 1 g sufficient for several products. Multi-species allocations improved omega-3 representation while remaining within practical intake limits and trace element-based screening thresholds. Community consumption data from Pacific Island children showed low and episodic seaweed intake, highlighting a gap between biomass potential and routine dietary use. These findings support safety-aware modeling as a preliminary screening and decision-support strategy for evaluating edible algal biomass before further product-specific validation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.